Literature DB >> 15534931

Effect of arsenic trioxide on human hepatocarcinoma in nude mice.

Hong-Yu Xu1, You-Lin Yang, Shu-Mei Liu, Li Bi, Shu-Xiang Chen.   

Abstract

AIM: To study the effect of arsenic trioxide (As(2)0(3)) on human hepatoma cell line BEL-7402 in vivo.
METHODS: Human hepatoma cell line BEL-7402 cultured in vitro was inoculated into nude mice and arsenic trioxide, 5-Fu and saline were injected into abdominal cavity of the nude mice respectively. The volumes of tumor and general conditions of the nude mice and structural changes of the liver and kidney were observed. Morphologic changes were studied under electron microscope. Expression of AFP was investigated by immunohistochemical method.
RESULTS: As(2)O(3) could inhibit the growth of tumor. The tumor growth inhibitory rate in mice treated with 2.5 mg/kg As(2)O(3) was 53.42% on the tenth day. The tumor growth inhibitory rate in mice treated with 5 mg/kg As(2)O(3) was 79.28% on the fifth day and 96.58% on the tenth day respectively. As(2)O(3) did not damage the liver and kidney of nude mice, or affect the blood system. Typical apoptotic morphological changes were found under electron microscope, and the change of mitochondria was obvious. The expression rate of AFP declined after treatment.
CONCLUSION: Arsenic trioxide can induce apoptosis of human hepatoma cells, and inhibit proliferation of tumor with no obvious side effects on liver and kidney.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15534931      PMCID: PMC4612017          DOI: 10.3748/wjg.v10.i24.3677

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  8 in total

1.  Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines.

Authors:  A König; L Wrazel; R P Warrell; R Rivi; P P Pandolfi; A Jakubowski; J L Gabrilove
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

2.  [Primary study of arsenic trioxide inhibits abdomino-metastatic tumor formation of human ovarian carcinoma in nude mice and its mechanisms].

Authors:  Shou-guo Huang; Bei-hua Kong; Rui-fang Yang; Sen Jiang
Journal:  Ai Zheng       Date:  2002-04

3.  Nuclear matrix associated protein PML: an arsenic trioxide apoptosis therapeutic target protein in HepG2 cells.

Authors:  Ding Yu; Zihui Wang; Liyuan Zhu; E C Chew
Journal:  Chin Med J (Engl)       Date:  2003-01       Impact factor: 2.628

4.  The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic.

Authors:  C Andre; M C Guillemin; J Zhu; M H Koken; F Quignon; L Herve; M K Chelbi-Alix; D Dhumeaux; Z Y Wang; L Degos; Z Chen; H de The
Journal:  Exp Cell Res       Date:  1996-12-15       Impact factor: 3.905

5.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.

Authors:  Z X Shen; G Q Chen; J H Ni; X S Li; S M Xiong; Q Y Qiu; J Zhu; W Tang; G L Sun; K Q Yang; Y Chen; L Zhou; Z W Fang; Y T Wang; J Ma; P Zhang; T D Zhang; S J Chen; Z Chen; Z Y Wang
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

6.  Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.

Authors:  Qun Liu; Susan Hilsenbeck; Yair Gazitt
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

7.  Induction of autophagic cell death in malignant glioma cells by arsenic trioxide.

Authors:  Takao Kanzawa; Yasuko Kondo; Hideaki Ito; Seiji Kondo; Isabelle Germano
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

Review 8.  [Research advances on effect of arsenic trioxide on tumor].

Authors:  Chun-qiong Feng; Wen-li Ma; Wen-ling Zheng
Journal:  Ai Zheng       Date:  2002-12
  8 in total
  7 in total

1.  Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

Authors:  Jennifer Wu; Charles Henderson; Lynn Feun; Peter Van Veldhuizen; Philip Gold; Hui Zheng; Theresa Ryan; Lawrence S Blaszkowsky; Haobin Chen; Max Costa; Barry Rosenzweig; MaryLynn Nierodzik; Howard Hochster; Franco Muggia; Giovanni Abbadessa; Jonathan Lewis; Andrew X Zhu
Journal:  Invest New Drugs       Date:  2009-06-30       Impact factor: 3.850

2.  Arterial embolization hyperthermia using As2O3 nanoparticles in VX2 carcinoma-induced liver tumors.

Authors:  Hui Yu; Guang-Yu Zhu; Rui-Zhi Xu; Huan-Zhang Niu; Qin Lu; Guo-Zhao Li; Zi-Yu Wang; Dong-Sheng Zhang; Ning Gu; Gao-Jun Teng
Journal:  PLoS One       Date:  2011-03-23       Impact factor: 3.240

3.  Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells.

Authors:  Ramon C Sun; Philip G Board; Anneke C Blackburn
Journal:  Mol Cancer       Date:  2011-11-18       Impact factor: 27.401

4.  Effects of arsenic trioxide on radiofrequency ablation of VX2 liver tumor: intraarterial versus intravenous administration.

Authors:  Nak Jong Seong; Chang Jin Yoon; Sung-Gwon Kang; Jin Wook Chung; Hyo-Cheol Kim; Jae Hyung Park
Journal:  Korean J Radiol       Date:  2012-03-07       Impact factor: 3.500

Review 5.  Synergistic Anticancer Activities of Natural Substances in Human Hepatocellular Carcinoma.

Authors:  Akiko Kojima-Yuasa; Xuedan Huang; Isao Matsui-Yuasa
Journal:  Diseases       Date:  2015-10-22

6.  Arsenic trioxide inhibits lung metastasis of mouse colon cancer via reducing the infiltration of regulatory T cells.

Authors:  Lei Wang; Xiang Hu; Yingxin Xu; Zhong Liu
Journal:  Tumour Biol       Date:  2016-09-27

7.  Evaluation on Efficacy and Safety of Arsenic Trioxide Plus Transcatheter Arterial Chemoembolization Versus Transcatheter Arterial Chemoembolization alone forzzm321990Unresectable Primary Liver Cancer

Authors:  Haitao Yang; Sijing Zhou; Ruifen Shen; Shuimei Luo; Lina Li; Heng Lin; Huijuan Chen; Ziyuan Liao; Wanzun Lin; Xianhe Xie
Journal:  Asian Pac J Cancer Prev       Date:  2017-10-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.